Medtide Inc. (HKG:3880)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
23.28
+0.88 (3.93%)
At close: Mar 10, 2026
Market Cap 3.18B
Revenue (ttm) 546.29M
Net Income (ttm) 121.20M
Shares Out 141.80M
EPS (ttm) 0.97
PE Ratio 23.10
Forward PE 13.83
Dividend n/a
Ex-Dividend Date n/a
Volume 100,200
Average Volume 109,734
Open 22.82
Previous Close 22.40
Day's Range 22.82 - 24.20
52-Week Range 21.50 - 41.72
Beta n/a
RSI 41.64
Earnings Date May 29, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, Pept... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 520
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3880
Full Company Profile

Financial Performance

In 2024, Medtide's revenue was 442.23 million, an increase of 31.31% compared to the previous year's 336.77 million. Earnings were 59.17 million, an increase of 21.00%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.